PC-002

Cothera’s lead program PC-002 is a first-in-class small molecule drug targeting Myc-mutated tumors.  With more than 50% of human cancers showing increased expression, Myc is regarded as one of the most important yet “undruggable” cancer targets.  With a unique mechanism of action, PC-002 selectively induces Myc protein degradation and cell apoptosis in Myc-dependent tumors, potentially targeting multiple indications in cancers involving Myc dysregulation.

PC-002 program is currently in Phase 2 clinical studies for multiple indications, including high-grade lymphoma in patients with c-MYC translocation (NCT05263583) as well as neuroendocrine prostate cancer in patients with n-MYC abnormality.